KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables - Other (2018 - 2021)

Alnylam Pharmaceuticals (ALNY) has disclosed Receivables - Other for 3 consecutive years, with $500.0 million as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Receivables - Other changed N/A year-over-year to $500.0 million, compared with a TTM value of $500.0 million through Jun 2021, changed N/A, and an annual FY2020 reading of $500.0 million, changed N/A over the prior year.
  • Receivables - Other was $500.0 million for Q2 2021 at Alnylam Pharmaceuticals, roughly flat from $500.0 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $500.0 million in Q3 2020 and bottomed at $12.5 million in Q4 2018.
  • Average Receivables - Other over 3 years is $402.5 million, with a median of $500.0 million recorded in 2020.